December 11th, 2017
jobs
homes

Menu
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fusion Pharmaceuticals Inc. - Common Shares (NQ:FUSN)

21.55 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fusion Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 Next >
FUSN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Fusion Pharmaceuticals Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments
AstraZeneca to acquire Fusion Pharmaceuticals for $21.00 per share cash plus $3.00 per share CVR upon regulatory milestone achievement, marking a significant $2.4 billion deal. Enhancing cancer... 
Via Benzinga
A Glimpse Into The Expert Outlook On Fusion Pharmaceuticals Through 7 Analysts
 
Via Benzinga
7 Low-Cost Call Options With High-Profit Potential
Call options are exciting but they can be a bit confusing. Let me guide you to compelling opportunities among certain hot names. 
Via InvestorPlace
Expert Outlook: Fusion Pharmaceuticals Through The Eyes Of 6 Analysts
 
Via Benzinga
A Closer Look at 4 Analyst Recommendations For Fusion Pharmaceuticals
 
Via Benzinga
Recap: Fusion Pharmaceuticals Q1 Earnings
 
Via Benzinga
Fusion Pharmaceuticals Earnings Perspective: Return On Capital Employed
 
Via Benzinga
Fusion Pharmaceuticals - Already Discovered By Wall Street
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. 
Via Talk Markets
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Why Dermata Therapeutics Shares Are Trading Higher By Over 57%; Here Are 20 Stocks Moving Premarket
Shares of Dermata Therapeutics, Inc. (NASDAQ: DRMA) rose sharply in pre-market trading after the company announced the issuance of a new patent in Japan for its DMT410 program for the treatment of... 
Via Benzinga
Topics Intellectual Property
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are worth checking on Friday as we lay out all of the biggest stories worth keeping tabs on this morning! 
Via InvestorPlace
Rivian Automotive Reports Weak Delivery Figures, Joins JOYY, MiMedx Group And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 200 points on Tuesday. 
Via Benzinga
Topics Stocks
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole... 
Via Benzinga
Meta To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth... 
Via Benzinga
Fusion's Pharma's Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% Upside
RBC Capital Markets initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), saying the radiopharmaceutical industry is a burgeoning area in therapeutics following the green light for Novartis... 
Via Benzinga
Agilent Posts Upbeat Results, Joins Burlington Stores, Hibbett And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling around 90 points on Tuesday. 
Via Benzinga
Topics Stocks
BWXT Medical Expands Collaboration with Fusion Pharmaceuticals Through Strengthened Actinium Supply and Access to Generator Technology
From BWX Technologies, Inc.
Via Business Wire
Fusion Pharmaceuticals Poised For Leadership In Targeted Cancer Therapies: Oppenheimer
Oppenheimer initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), citing the company's pipeline as among the best in the space with alpha-emitter-based targeted radionuclide therapies... 
Via Benzinga
Fusion Pharmaceuticals is Future Pillar of Cancer Treatment: Analyst
Raymond James has initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN) with an Outperform rating and a  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2023
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Top Ships Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Amesite Inc. (NASDAQ: AMST) shares jumped 123% to $0.6284 after the company announced GPT-3 powered functionality to its AI toolkit for customers and users. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Avis Budget, Zoetis, Palantir Technologies And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining over 50 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Dow Falls 150 Points; US Consumer Prices Rise 0.5% In January
U.S. stocks traded lower this morning, with the Dow Jones dropping around 150 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.46% to 34,089.44 while the NASDAQ fell 0.42%... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Fusion Pharma Raises $60M To Fund Acquisition Of Prostate Cancer-Targeted Radiopharmaceutical
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.